Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US-2015259296-A1 · Sep 17, 2015 · US
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9447071B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9447071-B2 |
| Application number | US-201514616548-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2015 |
| Priority date | Feb 7, 2014 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
First claim
Opening claim text (preview).
The invention claimed is: 1. A crystalline ansolvate of Compound 1: wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 2. The crystalline ansolvate of claim 1 , characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 3. The crystalline ansolvate of claim 1 , characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 4. The crystalline ansolvate of claim 1 , characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 5. The crystalline ansolvate of Compound 1 of claim 1 , wherein the crystalline ansolvate is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5 . 6. A composition comprising a crystalline ansolvate of Compound 1: wherein the crystalline ansolvate of Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 7. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 8. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 9. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 10. The composition of claim 6 , wherein the crystalline ansolvate is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of crystalline Form I. 11. The composition of claim 10 , wherein the crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1. 12. A pharmaceutical composition comprising a crystalline ansolvate of Compound 1: and at least one pharmaceutically acceptable excipient wherein the crystalline ansolvate of Compound 1 is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 13. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by at least two X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 14. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 15. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). 16. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of crystalline Form I. 17. The pharmaceutical composition of claim 16 , wherein the crystalline ansolvate of Compound 1 is substantially free of a solvated polymorph of Compound 1. 18. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of crystalline Material N. 19. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of amorphous forms of Compound 1. 20. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 10 mole % of crystalline Form I. 21. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 10 mole % of crystalline Material N. 22. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 10 mole % of amorphous forms of Compound 1. 23. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 5 mole % of crystalline Form I. 24. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 5 mole % of crystalline Material N. 25. The composition of claim 6 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 5 mole % of amorphous forms of Compound 1. 26. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of crystalline Material N. 27. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 25 mole % of amorphous forms of Compound 1. 28. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 10 mole % of crystalline Form I. 29. The pharmaceutical composition of claim 12 , wherein the crystalline ansolvate of Compound 1 is characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ), and less than 10 mole % of crystalline Material N. 30. The pharmaceutical composition of claim 12 , wherein the cry
Assignees
Inventors
Classifications
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
- A61K31/4439Primary
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Antineoplastic agents · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Drugs for disorders of the respiratory system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9447071B2 cover?
- Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
- Who is the assignee on this patent?
- Global Blood Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).